Xinda Bio's two monoclonal antibodies were approved clinically at the same time
Plos Comput Bio: Mathematical models reveal that children are twice as resistant to COVID-19 as adults
Changsheng Bio's vice chairman was sued by Societe Generale for 630 million yuan
Liaoning Chengda Bio to Hong Kong IPO: Gross margin is more than 80%
Abcam Finance is used to expand the research bio-reagent sales platform
Nasopharyngeal cancer immunotherapy! Junshi bio-anti-PD-1 therapy Terripri monoanti (toyo®
Contact Us
Trade Alert - Delivering the latest product trends and industry news straight to your inbox.
(We`ll never share your email address with a third-party.)
鲁ICP备16009155号-1 | Copyright@Qingdao Echemi Technology Co., Ltd.
Welcome to Echemi